Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Subscribe To Our Newsletter & Stay Updated